One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Rhythm Control of Atrial Fibrillation
Anne M. Gillis, Stephen B. Wilton
doi : 10.1161/CIRCULATIONAHA.120.051383
Circulation. 2021 | Volume 143, Issue 17: 1639–1641
Fruit and Vegetable Intake and Mortality
Dong D. Wang, Yanping Li, Shilpa N. Bhupathiraju, Bernard A. Rosner, Qi Sun, Edward L. Giovannucci, Eric B. Rimm, JoAnn E. Manson, Walter C. Willett, Meir J. Stampfer, Frank B. Hu
doi : 10.1161/CIRCULATIONAHA.120.048996
Circulation. 2021 | Volume 143, Issue 17: 1642–1654
The optimal intake levels of fruit and vegetables for maintaining long-term health are uncertain.
More Evidence for 5-a-Day for Fruit and Vegetables and a Greater Need for Translating Dietary Research Evidence to Practice
Naveed Sattar, Nita G. Forouhi
doi : 10.1161/CIRCULATIONAHA.121.053293
Circulation. 2021 | Volume 143, Issue 17: 1655–1658
Diagnostic Performance of High-Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite US Cohort
Brandon R. Allen, Robert H. Christenson, Scott A. Cohen, Richard Nowak, R. Gentry Wilkerson, Bryn Mumma, Troy Madsen, James McCord, Maite Huis in’t Veld, Michael Massoomi, Jason P. Stopyra, Cindy Montero, Michael T. Weaver, Kai Yang, Simon A. Mahler
doi : 10.1161/CIRCULATIONAHA.120.049298
Circulation. 2021 | Volume 143, Issue 17: 1659–1672
European data support the use of low high-sensitivity troponin (hs-cTn) measurements or a 0/1-hour (0/1-h) algorithm for myocardial infarction to exclude major adverse cardiac events (MACEs) among patients in the emergency department with possible acute coronary syndrome. However, modest US data exist to validate these strategies. This study evaluated the diagnostic performance of an initial hs-cTnT measure below the limit of quantification (LOQ: 6 ng/L), a 0/1-h algorithm, and their combination with history, ECG, age, risk factors, and initial troponin (HEART) scores for excluding MACE in a multisite US cohort.
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure
Michael E. Nassif, Mohammed Qintar, Sheryl L. Windsor, Rita Jermyn, David M. Shavelle, Fengming Tang, Sumant Lamba, Kunjan Bhatt, John Brush, Andrew Civitello, Robert Gordon, Orvar Jonsson, Brent Lampert, Jamie Pelzel, Mikhail N. Kosiborod
doi : 10.1161/CIRCULATIONAHA.120.052503
Circulation. 2021 | Volume 143, Issue 17: 1673–1686
Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those with HF and reduced ejection fraction, regardless of type 2 diabetes. Mechanisms of HF benefits remain unclear, and the effects of SGLT2 inhibitor on hemodynamics (filling pressures) are not known. The EMBRACE-HF trial (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure) was designed to address this knowledge gap.
Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death
Priya Umapathi, Olurotimi O. Mesubi, Partha S. Banerjee, Neha Abrol, Qinchuan Wang, Elizabeth D. Luczak, Yuejin Wu, Jonathan M. Granger, An-Chi Wei, Oscar E. Reyes Gaido, Liliana Florea, C. Conover Talbot Jr, Gerald W. Hart, Natasha E. Zachara, Mark E. Anderson
doi : 10.1161/CIRCULATIONAHA.120.051911
Circulation. 2021 | Volume 143, Issue 17: 1687–1703
Heart failure is a leading cause of death worldwide and is associated with the rising prevalence of obesity, hypertension, and diabetes. O-GlcNAcylation (the attachment of O-linked ?-N-acetylglucosamine [O-GlcNAc] moieties to cytoplasmic, nuclear, and mitochondrial proteins) is a posttranslational modification of intracellular proteins and serves as a metabolic rheostat for cellular stress. Total levels of O-GlcNAcylation are determined by nutrient and metabolic flux, in addition to the net activity of 2 enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Failing myocardium is marked by increased O-GlcNAcylation, but whether excessive O-GlcNAcylation contributes to cardiomyopathy and heart failure is unknown.
Single Nuclei Sequencing Reveals Novel Insights Into the Regulation of Cellular Signatures in Children With Dilated Cardiomyopathy
Luka Nicin, Wesley T. Abplanalp, Anne Sch?nzer, Anke Sprengel, David John, Hannah Mellentin, Lukas Tombor, Matthias Keuper, Evelyn Ullrich, Karin Klingel, Reinhard B. Dettmeyer, Jedrzej Hoffmann, Hakan Akintuerk, Christian Jux, Dietmar Schranz, Andreas M. Zeiher, Stefan Rupp, Stefanie Dimmeler
doi : 10.1161/CIRCULATIONAHA.120.051391
Circulation. 2021 | Volume 143, Issue 17: 1704–1719
Dilated cardiomyopathy (DCM) is a leading cause of death in children with heart failure. The outcome of pediatric heart failure treatment is inconsistent, and large cohort studies are lacking. Progress may be achieved through personalized therapy that takes age- and disease-related pathophysiology, pathology, and molecular fingerprints into account. We present single nuclei RNA sequencing from pediatric patients with DCM as the next step in identifying cellular signatures.
Highlights From the Circulation Family of Journals
doi : 10.1161/CIRCULATIONAHA.121.055032
Circulation. 2021 | Volume 143, Issue 17: 1720–1724
Dual-Chamber Pacemaker After Sinus Node Dysfunction and Enlarged Right Atrium
Emilio Arbas-Redondo, ?lvaro Montes-Mu?iz, Carlos A. ?lvarez-Ortega
doi : 10.1161/CIRCULATIONAHA.121.054510
Circulation. 2021 | Volume 143, Issue 17: 1725–1728
Serial Versus Single Cardiovascular Screening of Adolescent Athletes
Patrizio Sarto, Alessandro Zorzi, Laura Merlo, Teresina Vessella, Cinzia Pegoraro, Flaviano Giorgiano, Alessandro Patti, Martino Crosato, Gaetano Thiene, Jonathan A. Drezner, Cristina Basso, Domenico Corrado
doi : 10.1161/CIRCULATIONAHA.120.053168
Circulation. 2021 | Volume 143, Issue 17: 1729–1731
Letter by Zhang and Liu Regarding Article, “Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program”
Kaijie Zhang, Zhenjie Liu
doi : 10.1161/CIRCULATIONAHA.120.052263
Circulation. 2021 | Volume 143, Issue 17: e872
Response by Pan and Tsao to Letter Regarding Article, “Genetic Architecture of Abdominal Aortic Aneurysm in the Million Veteran Program”
Cuiping Pan, Philip S. Tsao
doi : 10.1161/CIRCULATIONAHA.121.053669
Circulation. 2021 | Volume 143, Issue 17: e873–e874
Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association
Mark A. Creager, Kunihiro Matsushita, Shipra Arya, Joshua A. Beckman, Sue Duval, Philip P. Goodney, J. Antonio T. Gutierrez, John A. Kaufman, Karen E. Joynt Maddox, Amy W. Pollak, Aruna D. Pradhan, Laurie P. Whitsel and On behalf of the American Heart Association Advocacy Coordinating Committee
doi : 10.1161/CIR.0000000000000967
Circulation. 2021 | Volume 143, Issue 17: e875–e891
Nontraumatic lower-extremity amputation is a devastating complication of peripheral artery disease (PAD) with a high mortality and medical expenditure. There are ?150?000 nontraumatic leg amputations every year in the United States, and most cases occur in patients with diabetes. Among patients with diabetes, after an ?40% decline between 2000 and 2009, the amputation rate increased by 50% from 2009 to 2015. A number of evidence-based diagnostic and therapeutic approaches for PAD can reduce amputation risk. However, their implementation and adherence are suboptimal. Some racial/ethnic groups have an elevated risk of PAD but less access to high-quality vascular care, leading to increased rates of amputation. To stop, and indeed reverse, the increasing trends of amputation, actionable policies that will reduce the incidence of critical limb ischemia and enhance delivery of optimal care are needed. This statement describes the impact of amputation on patients and society, summarizes medical approaches to identify PAD and prevent its progression, and proposes policy solutions to prevent limb amputation. Among the actions recommended are improving public awareness of PAD and greater use of effective PAD management strategies (eg, smoking cessation, use of statins, and foot monitoring/care in patients with diabetes). To facilitate the implementation of these recommendations, we propose several regulatory/legislative and organizational/institutional policies such as adoption of quality measures for PAD care; affordable prevention, diagnosis, and management; regulation of tobacco products; clinical decision support for PAD care; professional education; and dedicated funding opportunities to support PAD research. If these recommendations and proposed policies are implemented, we should be able to achieve the goal of reducing the rate of nontraumatic lower-extremity amputations by 20% by 2030.
Correction to: Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death
doi : 10.1161/CIR.0000000000000976
Circulation. 2021 | Volume 143, Issue 17: e892
